The third is distribution
By replicating these effects, GLP-1 drugs help regulate metabolism in people with type 2 diabetes and those struggling with obesity
Track these metrics weekly: Dose administered (mg, units, date, and time) Injection site (for rotation tracking) Side effects (type, severity 1 to 10, duration) Body weight (same time, same conditions each week) Body measurements (waist, hips, chest, if relevant) Appetite changes (subjective 1 to 10 scale) Energy levels (subjective 1 to 10 scale) Vial tracking (reconstitution date, volume remaining, expiration) This data tells you whether your dose is right, when to escalate, and whether the protocol is producing the desired outcomes
broadly safe for long-term use in appropriate patients , with monitoring for lean mass, gallbladder symptoms, and routine labs
Some reports link acute pancreatitis with GLP-1 agonists, but there are not enough data to establish a clear causal relationship
These individual contents supports 1st party COA that undergoes HPLC testing